CA2751906C - Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature - Google Patents
Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature Download PDFInfo
- Publication number
- CA2751906C CA2751906C CA2751906A CA2751906A CA2751906C CA 2751906 C CA2751906 C CA 2751906C CA 2751906 A CA2751906 A CA 2751906A CA 2751906 A CA2751906 A CA 2751906A CA 2751906 C CA2751906 C CA 2751906C
- Authority
- CA
- Canada
- Prior art keywords
- eye
- transducers
- eye ring
- segment shape
- sawn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 63
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 230000008397 ocular pathology Effects 0.000 claims abstract description 8
- 238000011269 treatment regimen Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 210000001508 eye Anatomy 0.000 description 121
- 208000010412 Glaucoma Diseases 0.000 description 32
- 210000004240 ciliary body Anatomy 0.000 description 32
- 238000000034 method Methods 0.000 description 31
- 238000001356 surgical procedure Methods 0.000 description 25
- 210000000695 crystalline len Anatomy 0.000 description 17
- 230000003902 lesion Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 210000001742 aqueous humor Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 210000001585 trabecular meshwork Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 208000002177 Cataract Diseases 0.000 description 8
- 208000002352 blister Diseases 0.000 description 7
- 210000000795 conjunctiva Anatomy 0.000 description 7
- 210000004087 cornea Anatomy 0.000 description 7
- 210000003786 sclera Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000007943 implant Substances 0.000 description 6
- 210000001328 optic nerve Anatomy 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 210000002159 anterior chamber Anatomy 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- 239000008177 pharmaceutical agent Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
- 230000004509 aqueous humor production Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 206010014801 endophthalmitis Diseases 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010012565 Developmental glaucoma Diseases 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 229960000722 brinzolamide Drugs 0.000 description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- AQOKCDNYWBIDND-ABRBVVEGSA-N 5-trans-17-phenyl trinor Prostaglandin F2alpha ethyl amide Chemical compound CCNC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-ABRBVVEGSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010051283 Fluid imbalance Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000006336 Juvenile glaucoma Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229940003677 alphagan Drugs 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229940098085 betagan Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 229940099238 diamox Drugs 0.000 description 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
- 229960000966 dipivefrine Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000028507 juvenile open angle glaucoma Diseases 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229940113006 travatan Drugs 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- 229940108420 trusopt Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00736—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments
- A61F9/00745—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments using mechanical vibrations, e.g. ultrasonic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2009/051892 WO2009103721A1 (en) | 2008-02-19 | 2009-02-18 | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
| EPPCT/EP2009/051892 | 2009-02-18 | ||
| PCT/EP2009/060678 WO2010094349A1 (en) | 2009-02-18 | 2009-08-18 | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2751906A1 CA2751906A1 (en) | 2010-08-26 |
| CA2751906C true CA2751906C (en) | 2018-03-27 |
Family
ID=41683368
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2751906A Active CA2751906C (en) | 2009-02-18 | 2009-08-18 | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature |
| CA2751908A Abandoned CA2751908A1 (en) | 2009-02-18 | 2009-08-26 | A method of treating an ocular pathology by applying ultrasound to the trabecular meshwork and device thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2751908A Abandoned CA2751908A1 (en) | 2009-02-18 | 2009-08-26 | A method of treating an ocular pathology by applying ultrasound to the trabecular meshwork and device thereof |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR101638140B1 (ru) |
| AU (1) | AU2009340220B2 (ru) |
| CA (2) | CA2751906C (ru) |
| IL (1) | IL214456A0 (ru) |
| RU (1) | RU2515509C2 (ru) |
| WO (2) | WO2010094349A1 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103025282B (zh) * | 2010-05-10 | 2015-03-11 | 特拉维夫大学拉玛特有限公司 | 通过将电磁能量引导到眼睛的角膜缘区域来治疗青光眼的系统 |
| US11771596B2 (en) * | 2010-05-10 | 2023-10-03 | Ramot At Tel-Aviv University Ltd. | System and method for treating an eye |
| FR2973250B1 (fr) * | 2011-03-29 | 2015-01-02 | Edap Tms France | Sonde de therapie pour le traitement de tissus par l'intermediaire d'ondes ultrasonores focalisees croisees |
| FR2973685B1 (fr) * | 2011-04-05 | 2014-11-28 | Eye Tech Care | Dispositif de therapie oculaire par ultrasons a reflecteur |
| DE102011116368A1 (de) * | 2011-10-17 | 2013-04-18 | Carl Zeiss Meditec Ag | Vorrichtung und Verfahren zur extrakapsulären chirurgischen Kataraktbehandlung |
| FR2983700B1 (fr) * | 2011-12-08 | 2014-03-07 | Eye Tech Care | Dispositif de succion pour le traitement d'une pathologie oculaire |
| DE102012019165B3 (de) | 2012-09-28 | 2013-07-18 | Carl Zeiss Meditec Ag | Handstück für die Phakoemulsifikation einer Augenlinse |
| RU2603718C2 (ru) * | 2015-04-17 | 2016-11-27 | ЗАКРЫТОЕ АКЦИОНЕРНОЕ ОБЩЕСТВО "ОПТИМЕДСЕРВИС" (ЗАО "Оптимедсервис") | Ультразвуковой инструмент факоэмульсификатора с трехмерными колебаниями |
| KR102446920B1 (ko) * | 2020-10-27 | 2022-09-23 | 웰스메디텍 주식회사 | 마이봄샘 기능부전의 증상 완화를 위한 초음파 처리 장치 |
| US20240139554A1 (en) * | 2021-02-26 | 2024-05-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Therapeutic ultrasonic transducers for the emission of focused ultrasound waves |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4484569A (en) * | 1981-03-13 | 1984-11-27 | Riverside Research Institute | Ultrasonic diagnostic and therapeutic transducer assembly and method for using |
| DE3932967A1 (de) * | 1989-10-03 | 1991-04-11 | Wolf Gmbh Richard | Ultraschall-stosswellenwandler |
| DE4430720A1 (de) * | 1993-12-21 | 1995-06-22 | Zeiss Carl Fa | Vorrichtung und Verfahren zur Laser-Cyclophotokoagulation |
| US5591127A (en) * | 1994-01-28 | 1997-01-07 | Barwick, Jr.; Billie J. | Phacoemulsification method and apparatus |
| US5645530A (en) * | 1995-08-28 | 1997-07-08 | Alcon Laboratories, Inc. | Phacoemulsification sleeve |
| US6419648B1 (en) * | 2000-04-21 | 2002-07-16 | Insightec-Txsonics Ltd. | Systems and methods for reducing secondary hot spots in a phased array focused ultrasound system |
| US8162858B2 (en) * | 2004-12-13 | 2012-04-24 | Us Hifu, Llc | Ultrasonic medical treatment device with variable focal zone |
| EP1738725A1 (de) * | 2005-06-30 | 2007-01-03 | Wavelight Laser Technologie AG | Einrichtung für die Augenchirurgie |
| US20070239011A1 (en) * | 2006-01-13 | 2007-10-11 | Mirabilis Medica, Inc. | Apparatus for delivering high intensity focused ultrasound energy to a treatment site internal to a patient's body |
| FR2906165B1 (fr) * | 2006-09-27 | 2009-01-09 | Corneal Ind Soc Par Actions Si | Systeme d'emission d'ultrasons et machine de traitement par ultrasons integrant ledit systeme |
| US8323296B2 (en) * | 2007-03-15 | 2012-12-04 | Boris Malyugin | Ring used in a small pupil phacoemulsification procedure |
| US20080275370A1 (en) * | 2007-05-01 | 2008-11-06 | Mcintyre Jon T | Apparatus and method for treating visual disorders |
-
2009
- 2009-08-18 WO PCT/EP2009/060678 patent/WO2010094349A1/en active Application Filing
- 2009-08-18 RU RU2011138181/14A patent/RU2515509C2/ru active
- 2009-08-18 AU AU2009340220A patent/AU2009340220B2/en active Active
- 2009-08-18 CA CA2751906A patent/CA2751906C/en active Active
- 2009-08-18 KR KR1020117020828A patent/KR101638140B1/ko active IP Right Grant
- 2009-08-26 WO PCT/EP2009/061014 patent/WO2010094353A1/en active Application Filing
- 2009-08-26 CA CA2751908A patent/CA2751908A1/en not_active Abandoned
-
2011
- 2011-08-04 IL IL214456A patent/IL214456A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL214456A0 (en) | 2011-09-27 |
| RU2515509C2 (ru) | 2014-05-10 |
| CA2751908A1 (en) | 2010-08-26 |
| KR20110126662A (ko) | 2011-11-23 |
| KR101638140B1 (ko) | 2016-07-11 |
| WO2010094353A1 (en) | 2010-08-26 |
| AU2009340220A1 (en) | 2011-09-01 |
| CA2751906A1 (en) | 2010-08-26 |
| WO2010094349A1 (en) | 2010-08-26 |
| AU2009340220B2 (en) | 2013-07-18 |
| RU2011138181A (ru) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9931245B2 (en) | High intensity focused ultrasound device with a concave segment shaped transducers for treatment of ocular pathology | |
| CA2751906C (en) | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature | |
| AU2009351378B2 (en) | Parameters for an ultrasound device comprising means to generate high intensity ultrasound beam | |
| EP2398432B1 (en) | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature | |
| WO2011083358A1 (en) | Device for treating an ocular pathology by applying doses of laser energy | |
| AU2009216751B2 (en) | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140723 |